Enal Razvi,
Managing Director,
Select Biosciences Inc
Enal Razvi, PhD is biotechnology analyst and Managing Director US at Select Biosciences. In this capacity he continuously tracks a number of fields in the scope of his industry coverage, authors market analysis reports in these areas, and works with companies worldwide in the areas of technology analysis, market research, strategy development, and operational roles. Dr. Razvi holds a doctoral degree in the biomedical sciences and was post-doctoral fellow under Ralph Steinman [Nobel Laureate in 2011] at The Rockefeller University, New York. For the last decade, Dr. Razvi has been focused on tracking the life sciences fields and has worked with numerous companies around the world.
Dr. Razvi can be reached at: enal@selectbio.us
|
|
Biomarkers and Companion Diagnostics (CDx): Results from Market TrackingThursday, 6 June 2013 at 14:00 Add to Calendar ▼2013-06-07 17:00:002013-06-07 18:00:00Europe/LondonKey Take-Aways and Closing Themes from the Summit.Translational Medicine Summit in HamburgHamburgSELECTBIOenquiries@selectbiosciences.com This presentation presents the latest market analysis performed by SELECTBIO tracking the companion diagnostics (CDx) marketplace with emphasis on various classes of biomarkers.
This presentation will frame and discuss the following topics:
1. Classes of Cancer Biomarkers 2. Publications Analysis of Various Biomarker Classes to Reveal Research Trends and "Hotspots" 3. Epigenetics Research Trends and Deployment as Biomarkers 4. microRNA Research Trends and Utility as Biomarkers 5. Exosomes Research and Biomarker Utility
All Registered Delegates will Receive the SELECTBIO MicroRNA and Epigenetics Research and Biomarkers 2013 Market Report underlying the Data/Analysis Presented Herein.
This 3-hour presentation will contain several blocks corresponding to the above topic areas and will be conducted in a round-table format with extensive discussions.
|